Several dermoscopic findings may help identify low-grade dysplastic nevi from other lesions, though the performance of the methods used was poor.

The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.